CoChat

How interleukin‐1β induces gouty arthritis

Open access
Dinarello, Charles A. · 2010 · Arthritis & Rheumatism
Cited by 58

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Recent clinical trials with IL-1β blockade have revealed an impressive and sustained reduction in recurrent attacks of gouty arthritis (1).Even with the use of allopurinol to reduce the systemic levels of uric acid and the anti-inflammatory properties of colchicine, there is no dearth of patients with recurrent episodes of painful gouty arthritis poorly controlled with these regimens who require intermittent courses of glucocorticoids.Thus, the success of IL-1β blocking therapies is a welcome addition for treating refractory gouty arthritis in these patients.Despite the availability of several widely used TNFα blocking therapies for rheumatoid arthritis and other autoimmune diseases, there is a paucity of reports that blocking TNFα provides an effective reduction in gout severity.One explanation for the lack of clinical trials of TNFα blockade in gout attacks is reluctance of subjecting these patients to suppression of host-defense by TNFα blockers.An alternative explanation is that efficacy of TNFα blockade in refractory gout is less than expected.One study reports a weak response with rather high doses of infliximab (2).There are also few publications on monosodium urate (MSU) crystals inducing TNFα from human and mouse cells unless co-stimulated with endotoxins.Therefore, IL-1β blockade may be used for inducing long-term remissions in refractory patients and replace glucocorticoids.If IL-1β blockade becomes the standard of care in refractory gout, it would be consistent with the unique role of IL-1β in the pathogenesis of auto-inflammatory diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.27663

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 58

Metadata

Authors
Dinarello, C. A.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2010-10-29
Volume
62
Issue
11
Pages
3140-3144
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2023269368
Cited by
58
References
1
FWCI
3.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.